Gland Pharma Limited (NSE:GLAND)
India
· Delayed Price · Currency is INR 1,822.20
-39.00 (-2.10%)
At close: Feb 27, 2026
Gland Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2017 |
| Revenue | 61,128 | 56,165 | 56,647 | 36,246 | 44,007 | 34,629 | Upgrade
|
| Revenue Growth (YoY) | 6.70% | -0.85% | 56.28% | -17.64% | 27.08% | 31.51% | Upgrade
|
| Cost of Revenue | 25,146 | 24,621 | 25,539 | 18,595 | 22,494 | 16,097 | Upgrade
|
| Gross Profit | 35,982 | 31,544 | 31,108 | 17,651 | 21,513 | 18,532 | Upgrade
|
| Selling, General & Admin | 16,011 | 14,120 | 12,668 | 4,047 | 3,397 | 3,122 | Upgrade
|
| Other Operating Expenses | 5,474 | 4,878 | 5,065 | 3,271 | 3,009 | 2,385 | Upgrade
|
| Operating Expenses | 25,638 | 22,822 | 21,393 | 8,807 | 7,513 | 6,498 | Upgrade
|
| Operating Income | 10,344 | 8,721 | 9,715 | 8,844 | 14,000 | 12,034 | Upgrade
|
| Interest Expense | -260.98 | -373.99 | -217.9 | -62.87 | -34.02 | -29.11 | Upgrade
|
| Interest & Investment Income | 2,043 | 2,043 | 1,506 | 1,794 | 1,386 | 859.49 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.63 | 2.63 | 106.05 | 571.45 | 792.05 | 405.26 | Upgrade
|
| Other Non Operating Income (Expenses) | 555.86 | 203.03 | 179.46 | -1.07 | -2.85 | 77.77 | Upgrade
|
| EBT Excluding Unusual Items | 12,684 | 10,596 | 11,288 | 11,146 | 16,142 | 13,348 | Upgrade
|
| Gain (Loss) on Sale of Investments | 12.27 | 12.27 | 3.48 | 28.48 | 44.89 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.32 | 0.32 | 2.49 | -0.81 | -1.78 | 0.24 | Upgrade
|
| Asset Writedown | 18.24 | 18.24 | - | -63.32 | - | - | Upgrade
|
| Other Unusual Items | -243.46 | - | - | -564.61 | - | - | Upgrade
|
| Pretax Income | 12,471 | 10,627 | 11,325 | 10,546 | 16,186 | 13,348 | Upgrade
|
| Income Tax Expense | 3,999 | 3,641 | 3,601 | 2,735 | 4,069 | 3,378 | Upgrade
|
| Net Income | 8,472 | 6,985 | 7,725 | 7,810 | 12,117 | 9,970 | Upgrade
|
| Net Income to Common | 8,472 | 6,985 | 7,725 | 7,810 | 12,117 | 9,970 | Upgrade
|
| Net Income Growth | 20.27% | -9.57% | -1.10% | -35.54% | 21.54% | 29.00% | Upgrade
|
| Shares Outstanding (Basic) | 165 | 165 | 165 | 165 | 164 | 158 | Upgrade
|
| Shares Outstanding (Diluted) | 165 | 165 | 165 | 165 | 165 | 158 | Upgrade
|
| Shares Change (YoY) | 0.02% | 0.01% | 0.03% | 0.09% | 3.96% | 2.15% | Upgrade
|
| EPS (Basic) | 51.42 | 42.40 | 46.90 | 47.44 | 73.81 | 63.07 | Upgrade
|
| EPS (Diluted) | 51.42 | 42.40 | 46.89 | 47.43 | 73.64 | 62.99 | Upgrade
|
| EPS Growth | 20.25% | -9.58% | -1.14% | -35.59% | 16.91% | 26.29% | Upgrade
|
| Free Cash Flow | - | 5,302 | 6,069 | 1,430 | 2,794 | 3,762 | Upgrade
|
| Free Cash Flow Per Share | - | 32.18 | 36.84 | 8.69 | 16.98 | 23.77 | Upgrade
|
| Dividend Per Share | 18.000 | 18.000 | 20.000 | - | - | - | Upgrade
|
| Dividend Growth | - | -10.00% | - | - | - | - | Upgrade
|
| Gross Margin | 58.86% | 56.16% | 54.92% | 48.70% | 48.88% | 53.52% | Upgrade
|
| Operating Margin | 16.92% | 15.53% | 17.15% | 24.40% | 31.81% | 34.75% | Upgrade
|
| Profit Margin | 13.86% | 12.44% | 13.64% | 21.55% | 27.53% | 28.79% | Upgrade
|
| Free Cash Flow Margin | - | 9.44% | 10.71% | 3.95% | 6.35% | 10.86% | Upgrade
|
| EBITDA | 14,191 | 12,314 | 12,968 | 10,310 | 15,102 | 13,020 | Upgrade
|
| EBITDA Margin | 23.21% | 21.93% | 22.89% | 28.44% | 34.32% | 37.60% | Upgrade
|
| D&A For EBITDA | 3,847 | 3,593 | 3,253 | 1,466 | 1,101 | 985.75 | Upgrade
|
| EBIT | 10,344 | 8,721 | 9,715 | 8,844 | 14,000 | 12,034 | Upgrade
|
| EBIT Margin | 16.92% | 15.53% | 17.15% | 24.40% | 31.81% | 34.75% | Upgrade
|
| Effective Tax Rate | 32.07% | 34.27% | 31.79% | 25.94% | 25.14% | 25.31% | Upgrade
|
| Revenue as Reported | 63,617 | 58,301 | 58,350 | 38,651 | 46,246 | 35,977 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.